The outlook for venture-capital investment sounds similar to the prognostications for the rest of the economy in 2011: better than 2010.However, the recent survey by the National Venture Capital Association contains one worrisome sign for the Philadelphia region. Life sciences may no longer be ascendant.
Attach your favorite reason for why that may be. The Food and Drug Administration is approving fewer new drugs than in the past. There is continuing uncertainty over how health-care reform will affect reimbursement for drugs and diagnostic tests. And quite frankly, the few life-sciences companies that did go public in 2010 saw their share prices sink.
There is no getting around that less investment flowing into life sciences would hamper an active corner of the region's start-up community.
To read the full, original article click on this link: PhillyInc: A worrisome note for Phila. in 2011: Life-sciences investment | Philadelphia Inquirer | 12/29/2010
Author: Mike Armstrong
